Jeremy W. Tigan

I'll research this attorney before writing the summary.

I'm seeing a potential name collision — let me disambiguate carefully.

The tracked case points to a Delaware attorney, not obviously a Fish & Richardson one. Let me verify firm affiliation and check for a separate "Jeremy W. Tigan."

Verification note (read first): The tracked appearance — Baby Jogger, LLC v. Baby Generation, Inc. d/b/a Mockingbird, C.A. No. 1:24-cv-00725-GBW (D. Del.) — is docketed to Jeremy A. Tigan of Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE), who signed the defendant's extension stipulations, motion to dismiss, letters, and motion to stay in that case. I could find no evidence of a "Jeremy W. Tigan," nor of any Fish & Richardson appearance for Mockingbird, in that docket or elsewhere. The profile's middle initial ("W.") and firm field ("Fish & Richardson") therefore could not be corroborated and appear to be data errors. The summary below describes the Morris Nichols attorney who matches the case.

Specialty / focus areas. Tigan is a Wilmington, Delaware–based IP litigation partner whose practice concentrates on patent infringement, trademark, and trade secret disputes in the District of Delaware, with appeals to the Federal and Third Circuits. Chambers and firm materials describe his technology mix as semiconductors, software, pharmaceuticals, and consumer products, with additional pharmaceutical/ANDA and internet-sector experience. His docketed matters reflect that breadth: Hatch-Waxman/ANDA work (Galderma v. Teva; Integra LifeSciences v. HyperBranch; Recro Gainesville v. Actavis; Cadence Pharms./SCR Pharmatop v. InnoPharma; a Federal Circuit appeal at No. 17-1822), chemicals (Superior Oil, Buckman, and Hydrite actions against Solenis), biofuels (Butamax v. Gevo), and mechanical/consumer-goods patents — the latter being the category of the tracked stroller case (Baby Jogger's asserted patents cover removable second-seat attachments for convertible strollers).

Side preference. The tracked data show 0 plaintiff-side and 1 defendant-side appearance, and the public record is consistent with a genuine two-sided practice rather than a one-sided one. He has defended accused infringers (Mockingbird; Cytek Biosciences in Beckman Coulter v. Cytek; bluebird bio), but has also acted for patent owners and plaintiffs, including a Delaware jury trial for Northwestern University on three collaborative-robot-system patents, as well as representations for Merck and Jazz Pharmaceuticals. He is described in Chambers as acting as both lead counsel and Delaware/local counsel.

Firm context and notable matters. He joined Morris Nichols in 2008 and became a partner effective January 1, 2017; he remains in the firm's IP Litigation Group. Verifiable results include a May 16, 2025 Delaware summary judgment of noninfringement for bluebird bio (with Jack Blumenfeld, Anthony Raucci, and Paul Hastings as co-counsel), representation of Qorvo alongside Sheppard Mullin (reported October 2024), and the Northwestern University jury trial win on collaborative robot patents reported in IAM Patent 1000. In the tracked matter, the practical postures have been defensive: a pending motion to dismiss the first amended complaint for lack of standing and a motion to stay filed August 20, 2025 pending that ruling. Five IPRs against the asserted Baby Jogger patents were filed in June 2025 by Mockingbird and co-petitioners Evenflo and UPPAbaby; at least one (IPR2025-01095) was terminated by discretionary denial on December 1, 2025.

PTAB / IPR experience. I could not verify a regular PTAB practice. The IPR petitions in the Baby Jogger matter name Joseph W. Staley of Perilla Knox & Hildebrandt as lead counsel, not Tigan, and no PTAB filings naming him surfaced in my searches. Treat his IPR/PGR activity as unconfirmed.

Bar / education. Admitted in Delaware (2008); J.D., cum laude, George Mason University School of Law (now Antonin Scalia Law School), 2007; M.A., George Washington University; B.S., University of Oregon. He served as president of the Delaware Chapter of the Federal Bar Association (2021–2023). Co-author of "Pretrial Preparation," in ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators (ABA, 2012).